img

Global Endogenous Peptide Substances Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Endogenous Peptide Substances Market Research Report 2024

According to MRAResearch’s new survey, global Endogenous Peptide Substances market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033.
The driving force of endogenous peptides mainly comes from the following aspects
Biological functions of bioactive peptidesBioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and developmentWith the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technologySince the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indicationsAs the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Endogenous Peptide Substances market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc.
Endo International Plc
Biosynth Carbosynth
Lannett Co. Inc.
Pfizer
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides
Segment by Type
Neuropeptides
Hormones
Cytokines
Peptide Hormones
Bioactive Peptides

Segment by Application


Research
Medicine
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Endogenous Peptide Substances report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Endogenous Peptide Substances Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Neuropeptides
1.2.3 Hormones
1.2.4 Cytokines
1.2.5 Peptide Hormones
1.2.6 Bioactive Peptides
1.3 Market by Application
1.3.1 Global Endogenous Peptide Substances Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Research
1.3.3 Medicine
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Endogenous Peptide Substances Market Perspective (2018-2033)
2.2 Endogenous Peptide Substances Growth Trends by Region
2.2.1 Global Endogenous Peptide Substances Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Endogenous Peptide Substances Historic Market Size by Region (2018-2023)
2.2.3 Endogenous Peptide Substances Forecasted Market Size by Region (2024-2033)
2.3 Endogenous Peptide Substances Market Dynamics
2.3.1 Endogenous Peptide Substances Industry Trends
2.3.2 Endogenous Peptide Substances Market Drivers
2.3.3 Endogenous Peptide Substances Market Challenges
2.3.4 Endogenous Peptide Substances Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Endogenous Peptide Substances Players by Revenue
3.1.1 Global Top Endogenous Peptide Substances Players by Revenue (2018-2023)
3.1.2 Global Endogenous Peptide Substances Revenue Market Share by Players (2018-2023)
3.2 Global Endogenous Peptide Substances Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Endogenous Peptide Substances Revenue
3.4 Global Endogenous Peptide Substances Market Concentration Ratio
3.4.1 Global Endogenous Peptide Substances Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Endogenous Peptide Substances Revenue in 2022
3.5 Endogenous Peptide Substances Key Players Head office and Area Served
3.6 Key Players Endogenous Peptide Substances Product Solution and Service
3.7 Date of Enter into Endogenous Peptide Substances Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Endogenous Peptide Substances Breakdown Data by Type
4.1 Global Endogenous Peptide Substances Historic Market Size by Type (2018-2023)
4.2 Global Endogenous Peptide Substances Forecasted Market Size by Type (2024-2033)
5 Endogenous Peptide Substances Breakdown Data by Application
5.1 Global Endogenous Peptide Substances Historic Market Size by Application (2018-2023)
5.2 Global Endogenous Peptide Substances Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Endogenous Peptide Substances Market Size (2018-2033)
6.2 North America Endogenous Peptide Substances Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Endogenous Peptide Substances Market Size by Country (2018-2023)
6.4 North America Endogenous Peptide Substances Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Endogenous Peptide Substances Market Size (2018-2033)
7.2 Europe Endogenous Peptide Substances Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Endogenous Peptide Substances Market Size by Country (2018-2023)
7.4 Europe Endogenous Peptide Substances Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Endogenous Peptide Substances Market Size (2018-2033)
8.2 Asia-Pacific Endogenous Peptide Substances Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Endogenous Peptide Substances Market Size by Region (2018-2023)
8.4 Asia-Pacific Endogenous Peptide Substances Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Endogenous Peptide Substances Market Size (2018-2033)
9.2 Latin America Endogenous Peptide Substances Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Endogenous Peptide Substances Market Size by Country (2018-2023)
9.4 Latin America Endogenous Peptide Substances Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Endogenous Peptide Substances Market Size (2018-2033)
10.2 Middle East & Africa Endogenous Peptide Substances Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Endogenous Peptide Substances Market Size by Country (2018-2023)
10.4 Middle East & Africa Endogenous Peptide Substances Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Assertio Therapeutics Inc.
11.1.1 Assertio Therapeutics Inc. Company Detail
11.1.2 Assertio Therapeutics Inc. Business Overview
11.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Introduction
11.1.4 Assertio Therapeutics Inc. Revenue in Endogenous Peptide Substances Business (2018-2023)
11.1.5 Assertio Therapeutics Inc. Recent Development
11.2 Cipher Pharmaceuticals Inc.
11.2.1 Cipher Pharmaceuticals Inc. Company Detail
11.2.2 Cipher Pharmaceuticals Inc. Business Overview
11.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Introduction
11.2.4 Cipher Pharmaceuticals Inc. Revenue in Endogenous Peptide Substances Business (2018-2023)
11.2.5 Cipher Pharmaceuticals Inc. Recent Development
11.3 Endo International Plc
11.3.1 Endo International Plc Company Detail
11.3.2 Endo International Plc Business Overview
11.3.3 Endo International Plc Endogenous Peptide Substances Introduction
11.3.4 Endo International Plc Revenue in Endogenous Peptide Substances Business (2018-2023)
11.3.5 Endo International Plc Recent Development
11.4 Biosynth Carbosynth
11.4.1 Biosynth Carbosynth Company Detail
11.4.2 Biosynth Carbosynth Business Overview
11.4.3 Biosynth Carbosynth Endogenous Peptide Substances Introduction
11.4.4 Biosynth Carbosynth Revenue in Endogenous Peptide Substances Business (2018-2023)
11.4.5 Biosynth Carbosynth Recent Development
11.5 Lannett Co. Inc.
11.5.1 Lannett Co. Inc. Company Detail
11.5.2 Lannett Co. Inc. Business Overview
11.5.3 Lannett Co. Inc. Endogenous Peptide Substances Introduction
11.5.4 Lannett Co. Inc. Revenue in Endogenous Peptide Substances Business (2018-2023)
11.5.5 Lannett Co. Inc. Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Endogenous Peptide Substances Introduction
11.6.4 Pfizer Revenue in Endogenous Peptide Substances Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Endogenous Peptide Substances Introduction
11.7.4 Johnson & Johnson Revenue in Endogenous Peptide Substances Business (2018-2023)
11.7.5 Johnson & Johnson Recent Development
11.8 Peptide Institute
11.8.1 Peptide Institute Company Detail
11.8.2 Peptide Institute Business Overview
11.8.3 Peptide Institute Endogenous Peptide Substances Introduction
11.8.4 Peptide Institute Revenue in Endogenous Peptide Substances Business (2018-2023)
11.8.5 Peptide Institute Recent Development
11.9 Abbexa
11.9.1 Abbexa Company Detail
11.9.2 Abbexa Business Overview
11.9.3 Abbexa Endogenous Peptide Substances Introduction
11.9.4 Abbexa Revenue in Endogenous Peptide Substances Business (2018-2023)
11.9.5 Abbexa Recent Development
11.10 Phoenix Pharmaceuticals
11.10.1 Phoenix Pharmaceuticals Company Detail
11.10.2 Phoenix Pharmaceuticals Business Overview
11.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Introduction
11.10.4 Phoenix Pharmaceuticals Revenue in Endogenous Peptide Substances Business (2018-2023)
11.10.5 Phoenix Pharmaceuticals Recent Development
11.11 Creative Peptides
11.11.1 Creative Peptides Company Detail
11.11.2 Creative Peptides Business Overview
11.11.3 Creative Peptides Endogenous Peptide Substances Introduction
11.11.4 Creative Peptides Revenue in Endogenous Peptide Substances Business (2018-2023)
11.11.5 Creative Peptides Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Endogenous Peptide Substances Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Neuropeptides
Table 3. Key Players of Hormones
Table 4. Key Players of Cytokines
Table 5. Key Players of Peptide Hormones
Table 6. Key Players of Bioactive Peptides
Table 7. Global Endogenous Peptide Substances Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Endogenous Peptide Substances Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Endogenous Peptide Substances Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Endogenous Peptide Substances Market Share by Region (2018-2023)
Table 11. Global Endogenous Peptide Substances Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Endogenous Peptide Substances Market Share by Region (2024-2033)
Table 13. Endogenous Peptide Substances Market Trends
Table 14. Endogenous Peptide Substances Market Drivers
Table 15. Endogenous Peptide Substances Market Challenges
Table 16. Endogenous Peptide Substances Market Restraints
Table 17. Global Endogenous Peptide Substances Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Endogenous Peptide Substances Market Share by Players (2018-2023)
Table 19. Global Top Endogenous Peptide Substances Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endogenous Peptide Substances as of 2022)
Table 20. Ranking of Global Top Endogenous Peptide Substances Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Endogenous Peptide Substances Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Endogenous Peptide Substances Product Solution and Service
Table 24. Date of Enter into Endogenous Peptide Substances Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Endogenous Peptide Substances Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Endogenous Peptide Substances Revenue Market Share by Type (2018-2023)
Table 28. Global Endogenous Peptide Substances Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Endogenous Peptide Substances Revenue Market Share by Type (2024-2033)
Table 30. Global Endogenous Peptide Substances Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Endogenous Peptide Substances Revenue Market Share by Application (2018-2023)
Table 32. Global Endogenous Peptide Substances Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Endogenous Peptide Substances Revenue Market Share by Application (2024-2033)
Table 34. North America Endogenous Peptide Substances Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. North America Endogenous Peptide Substances Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Endogenous Peptide Substances Market Size by Country (2024-2033) & (US$ Million)
Table 37. Europe Endogenous Peptide Substances Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. Europe Endogenous Peptide Substances Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Endogenous Peptide Substances Market Size by Country (2024-2033) & (US$ Million)
Table 40. Asia-Pacific Endogenous Peptide Substances Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 41. Asia-Pacific Endogenous Peptide Substances Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Endogenous Peptide Substances Market Size by Region (2024-2033) & (US$ Million)
Table 43. Latin America Endogenous Peptide Substances Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Latin America Endogenous Peptide Substances Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Endogenous Peptide Substances Market Size by Country (2024-2033) & (US$ Million)
Table 46. Middle East & Africa Endogenous Peptide Substances Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 47. Middle East & Africa Endogenous Peptide Substances Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Endogenous Peptide Substances Market Size by Country (2024-2033) & (US$ Million)
Table 49. Assertio Therapeutics Inc. Company Detail
Table 50. Assertio Therapeutics Inc. Business Overview
Table 51. Assertio Therapeutics Inc. Endogenous Peptide Substances Product
Table 52. Assertio Therapeutics Inc. Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 53. Assertio Therapeutics Inc. Recent Development
Table 54. Cipher Pharmaceuticals Inc. Company Detail
Table 55. Cipher Pharmaceuticals Inc. Business Overview
Table 56. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product
Table 57. Cipher Pharmaceuticals Inc. Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 58. Cipher Pharmaceuticals Inc. Recent Development
Table 59. Endo International Plc Company Detail
Table 60. Endo International Plc Business Overview
Table 61. Endo International Plc Endogenous Peptide Substances Product
Table 62. Endo International Plc Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 63. Endo International Plc Recent Development
Table 64. Biosynth Carbosynth Company Detail
Table 65. Biosynth Carbosynth Business Overview
Table 66. Biosynth Carbosynth Endogenous Peptide Substances Product
Table 67. Biosynth Carbosynth Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 68. Biosynth Carbosynth Recent Development
Table 69. Lannett Co. Inc. Company Detail
Table 70. Lannett Co. Inc. Business Overview
Table 71. Lannett Co. Inc. Endogenous Peptide Substances Product
Table 72. Lannett Co. Inc. Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 73. Lannett Co. Inc. Recent Development
Table 74. Pfizer Company Detail
Table 75. Pfizer Business Overview
Table 76. Pfizer Endogenous Peptide Substances Product
Table 77. Pfizer Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 78. Pfizer Recent Development
Table 79. Johnson & Johnson Company Detail
Table 80. Johnson & Johnson Business Overview
Table 81. Johnson & Johnson Endogenous Peptide Substances Product
Table 82. Johnson & Johnson Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 83. Johnson & Johnson Recent Development
Table 84. Peptide Institute Company Detail
Table 85. Peptide Institute Business Overview
Table 86. Peptide Institute Endogenous Peptide Substances Product
Table 87. Peptide Institute Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 88. Peptide Institute Recent Development
Table 89. Abbexa Company Detail
Table 90. Abbexa Business Overview
Table 91. Abbexa Endogenous Peptide Substances Product
Table 92. Abbexa Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 93. Abbexa Recent Development
Table 94. Phoenix Pharmaceuticals Company Detail
Table 95. Phoenix Pharmaceuticals Business Overview
Table 96. Phoenix Pharmaceuticals Endogenous Peptide Substances Product
Table 97. Phoenix Pharmaceuticals Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 98. Phoenix Pharmaceuticals Recent Development
Table 99. Creative Peptides Company Detail
Table 100. Creative Peptides Business Overview
Table 101. Creative Peptides Endogenous Peptide Substances Product
Table 102. Creative Peptides Revenue in Endogenous Peptide Substances Business (2018-2023) & (US$ Million)
Table 103. Creative Peptides Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Endogenous Peptide Substances Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Endogenous Peptide Substances Market Share by Type: 2022 VS 2033
Figure 3. Neuropeptides Features
Figure 4. Hormones Features
Figure 5. Cytokines Features
Figure 6. Peptide Hormones Features
Figure 7. Bioactive Peptides Features
Figure 8. Global Endogenous Peptide Substances Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Endogenous Peptide Substances Market Share by Application: 2022 VS 2033
Figure 10. Research Case Studies
Figure 11. Medicine Case Studies
Figure 12. Others Case Studies
Figure 13. Endogenous Peptide Substances Report Years Considered
Figure 14. Global Endogenous Peptide Substances Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Endogenous Peptide Substances Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Endogenous Peptide Substances Market Share by Region: 2022 VS 2033
Figure 17. Global Endogenous Peptide Substances Market Share by Players in 2022
Figure 18. Global Top Endogenous Peptide Substances Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endogenous Peptide Substances as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Endogenous Peptide Substances Revenue in 2022
Figure 20. North America Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Endogenous Peptide Substances Market Share by Country (2018-2033)
Figure 22. United States Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Endogenous Peptide Substances Market Share by Country (2018-2033)
Figure 26. Germany Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. France Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. U.K. Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Italy Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Russia Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Nordic Countries Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific Endogenous Peptide Substances Market Share by Region (2018-2033)
Figure 34. China Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Japan Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. South Korea Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Southeast Asia Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. India Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Australia Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America Endogenous Peptide Substances Market Share by Country (2018-2033)
Figure 42. Mexico Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Brazil Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa Endogenous Peptide Substances Market Share by Country (2018-2033)
Figure 46. Turkey Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Saudi Arabia Endogenous Peptide Substances Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Assertio Therapeutics Inc. Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 49. Cipher Pharmaceuticals Inc. Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 50. Endo International Plc Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 51. Biosynth Carbosynth Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 52. Lannett Co. Inc. Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 53. Pfizer Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 54. Johnson & Johnson Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 55. Peptide Institute Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 56. Abbexa Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 57. Phoenix Pharmaceuticals Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 58. Creative Peptides Revenue Growth Rate in Endogenous Peptide Substances Business (2018-2023)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries